Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.87 USD
Change Today -0.12 / -6.03%
Volume 54.7K
ALXA On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

alexza pharmaceuticals inc (ALXA) Snapshot

Open
$1.99
Previous Close
$1.99
Day High
$1.99
Day Low
$1.71
52 Week High
07/16/14 - $5.27
52 Week Low
12/17/14 - $1.25
Market Cap
36.3M
Average Volume 10 Days
26.9K
EPS TTM
$-2.38
Shares Outstanding
19.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXZA PHARMACEUTICALS INC (ALXA)

alexza pharmaceuticals inc (ALXA) Related Businessweek News

No Related Businessweek News Found

alexza pharmaceuticals inc (ALXA) Details

Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide. The company’s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. It offers ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company also engages in developing AZ-002 (Staccato alprazolam) for treating patients with acute repetitive seizures, as well as in Phase 2a study for patients with epilepsy; and AZ-007 (Staccato zaleplon) for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. It has collaboration agreement with Grupo Ferrer Internacional S.A. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.Alexza Pharmaceuticals, Inc. was incorporated in 2000 and is based in Mountain View, California.

81 Employees
Last Reported Date: 03/13/15
Founded in 2000

alexza pharmaceuticals inc (ALXA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $526.0K
Compensation as of Fiscal Year 2013.

alexza pharmaceuticals inc (ALXA) Key Developments

Alexza Pharmaceuticals Inc. Announces Two Management Promotions

Alexza Pharmaceuticals Inc. announced two management promotions. Dr. Edwin S. Kamemoto has been promoted to the newly created position of Executive Vice President, R&D and Quality. In this new role, Dr. Kamemoto will be responsible for research and development, regulatory affairs, clinical research, pharmacovigilance, and the quality functions at Alexza. Dr. Lori H. Takahashi has been promoted to the newly created position of Vice President, Pharmaceutical R&D and Quality. In this new role, Dr. Takahashi will be responsible for product research and development, toxicology, pharmacokinetics/ADME (PK/ADME), analytical development, and day-to-day leadership of the quality functions at Alexza. Dr. Kamemoto joined Alexza in 2006 as Associate Director, Regulatory Affairs, and was promoted to Director, Regulatory Affairs in 2007, to Senior Director, Regulatory Affairs in 2008, to Executive Director, Regulatory Affairs in 2010, and to Vice President, Regulatory Affairs in 2012.

Alexza Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt

Alexza Pharmaceuticals Inc. filed its 10-K on Mar 13, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Alexza Pharmaceuticals Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Alexza Pharmaceuticals Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. The net loss for the fourth quarter was $6.7 million compared to $5.7 million during the same quarter in 2013. Revenue was $1,454,000 compared to $1,309,000 a year ago. Loss from operations was $7,264,000 compared to $9,357,000 a year ago. Basic and diluted loss per share was $0.35 compared to $0.33 a year ago. The net loss for the years ended December 31, 2014 and 2013 was $36.7 million and $39.6 million, respectively. Revenue was $5,561,000 compared to $47,839,000 a year ago. Loss from operations was $37,456,000 compared to income from operations of $1,770,000 a year ago. Basic and diluted loss per share was $2.07 compared to $2.38 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXA:US $1.87 USD -0.12

ALXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALXA.
View Industry Companies
 

Industry Analysis

ALXA

Industry Average

Valuation ALXA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXZA PHARMACEUTICALS INC, please visit www.alexza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.